Condition: Non-small Cell Lung Cancer · Colorectal Cancer · Pancreatic Cancer · Sponsor: Qilu Pharmaceutical Co., Ltd.
QLC1101 is a selective reversible inhibitor of KRAS G12D, with the dosage form of capsules and administration route of oral administration. In the first-in-humans (FIH) study, the sponsor will explore the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of QLC1101 in subjects with advanced solid tumors harboring a KRAS G12D mutation. The FIH study includes dose escalation, PK expansion, and efficacy expansion.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Guangdong Pharmaceutical University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Harbin Medical university cancer hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Jiangxi Cancer Hospital | Nanchang, Jiangxi, China | Not Yet Recruiting |
| Shanghai east hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Yunnan Cancer Hospital | Kunming, Yunnan, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06403735